Bytom

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy … Pending
  2024-514388-24-00 4 Knee osteoarthritis
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5 Psoriatic Arthritis
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Pending
  2025-523579-47-00 4 moderate to severe rheumatoid arthritis (RA)
• A clinical study of tulisokibart in people with psoriatic arthritis (MK-7240-015) Recruiting
  2025-520997-21-00 4 2026-05-08 Psoriatic arthritis​​
• A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting
  2025-522782-30-00 3 2026-04-07 CCI
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or … Recruiting
  2025-521034-28-00 4 2025-12-05 Moderate to Severe Rheumatoid Arthritis (RA)
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with A … Recruiting
  2023-510242-24-00 6 2025-12-01 Psoriatic Arthritis
• A clinical study of tulisokibart in people with rheumatoid arthritis (MK-7240-014) Recruiting
  2025-521745-25-00 4 2025-11-06 Rheumatoid Arthritis
• A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases Recruiting
  2024-517681-41-00 1 2025-08-29 Systemic Sclerosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally i … Recruiting
  2024-519919-34-00 5 2025-08-18 Plaque psoriasis
• A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting
  2024-513111-27-00 5 2025-06-26 Psoriatic Arthritis
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting
  2023-509743-27-00 4 2022-04-29 Systemic sclerosis associated with interstitial lung disease

Showing 1–24 of 50 trials